PPARβ/δ Regulates Glucocorticoid- and Sepsis-induced FOXO1 Activation and Muscle Wasting
Overview
Affiliations
FOXO1 is involved in glucocorticoid- and sepsis-induced muscle wasting, in part reflecting regulation of atrogin-1 and MuRF1. Mechanisms influencing FOXO1 expression in muscle wasting are poorly understood. We hypothesized that the transcription factor peroxisome proliferator-activated receptor β/δ (PPARβ/δ) upregulates muscle FOXO1 expression and activity with a downstream upregulation of atrogin-1 and MuRF1 expression during sepsis and glucocorticoid treatment and that inhibition of PPARβ/δ activity can prevent muscle wasting. We found that activation of PPARβ/δ in cultured myotubes increased FOXO1 activity, atrogin-1 and MuRF1 expression, protein degradation and myotube atrophy. Treatment of myotubes with dexamethasone increased PPARβ/δ expression and activity. Dexamethasone-induced FOXO1 activation and atrogin-1 and MuRF1 expression, protein degradation, and myotube atrophy were inhibited by PPARβ/δ blocker or siRNA. Importantly, muscle wasting induced in rats by dexamethasone or sepsis was prevented by treatment with a PPARβ/δ inhibitor. The present results suggest that PPARβ/δ regulates FOXO1 activation in glucocorticoid- and sepsis-induced muscle wasting and that treatment with a PPARβ/δ inhibitor may ameliorate loss of muscle mass in these conditions.
Wei X, Jiang W, Wang Z, Li Y, Jing Y, Han Y Cell Mol Biol Lett. 2025; 30(1):8.
PMID: 39833662 PMC: 11744841. DOI: 10.1186/s11658-025-00686-x.
Acute Sarcopenia: Mechanisms and Management.
Damanti S, Senini E, De Lorenzo R, Merolla A, Santoro S, Festorazzi C Nutrients. 2024; 16(20).
PMID: 39458423 PMC: 11510680. DOI: 10.3390/nu16203428.
Badenes Bonet D, Caguana Velez O, Duran Jorda X, Comas Serrano M, Posso Rivera M, Admetllo M J Clin Med. 2023; 12(12).
PMID: 37373850 PMC: 10299438. DOI: 10.3390/jcm12124158.
Oligonucleotide Therapeutics for Age-Related Musculoskeletal Disorders: Successes and Challenges.
Nicholson T, Sagmeister M, Wijesinghe S, Farah H, Hardy R, Jones S Pharmaceutics. 2023; 15(1).
PMID: 36678864 PMC: 9866666. DOI: 10.3390/pharmaceutics15010237.
The Effects of COVID-19 on Skeletal Muscles, Muscle Fatigue and Rehabilitation Programs Outcomes.
Pescaru C, Maritescu A, Costin E, Traila D, Marc M, Trusculescu A Medicina (Kaunas). 2022; 58(9).
PMID: 36143878 PMC: 9500689. DOI: 10.3390/medicina58091199.